Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.

胶原酶溶组织梭菌（CCH、Xiaflex、Xiapex）是唯一获得 FDA 批准的用于治疗佩罗尼氏病的药物。目前尚不清楚从业者如何在自己的实践中实际使用 CCH。该研究的目的是：(1) 确定从业者 CCH 实践模式的变异性，(2) 评估对包装说明书说明的遵守情况，以及 (3) 评估提供者的满意度是否与对说明的遵守情况相关。向来自欧盟、美国、加拿大和澳大利亚的国际性医学协会 (ISSM) 的 1270 名成员分发了一项包含 30 个问题的在线调查。在 30 个问题中，10 个调查问题只有一个与 CCH 包装插页建议一致的回答。根据正确回答这些问题的数量，计算每个调查参与者的“依从性”分数。不同组的平均依从性分数使用学生的t检验。卡方检验用于确定分类变量之间的关联。在 202 份回复中，有 132 名从业者报告使用 CCH，来自提供 CCH 的国家的 1270 名 ISSM 成员（回复率为 10.4%）。来自美国以外的从业者更可能对 CCH 感到满意（p  = 0.006），更有经验的用户（>20 次使用）比经验不足的用户（<10 次使用）更有可能感到满意（p = 0.046）。满意的 CCH 用户的依从性分数与不满意的用户没有显着差异。尽管 67% 的从业者认为他们遵循了包装说明书指南，但只有 11% 的从业者遵守了调查评估的所有建议。对包装说明书指南的治疗依从性似乎与提供者满意度无关。我们相信看到这些实践模式的快照是有用的，因此从业者可能会根据支持替代管理方法的更新数据来适应他们自己的实践。